Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Vor Biopharma (VOR – Research Report). The associated price ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Beam Therapeutics Inc (BEAM) reports encouraging clinical data for BEAM-101 in sickle cell treatment, while maintaining a ...

Participants receiving EBX-102 showed statistically significant changes to stool bacterial metabolites. Shotgun sequencing is ongoing and will provide additional insights into engraftment. Venous ...

Groundbreaking bone marrow transplant saves 10-month-old boy with rare genetic immunodeficiency, funded by The Hans ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

All 3 patients with MDS in the non-TBI group experienced relapse, with 2 successfully treated with a second transplant. In ...

Hematopoietic stem cell transplant (HSCT) from deceased donors appears feasible, safe, and effective, according to results from one of the first patients to receive this treatment.

William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating today. Sami Corwin’s rating is ...